JP2010513397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513397A5 JP2010513397A5 JP2009542043A JP2009542043A JP2010513397A5 JP 2010513397 A5 JP2010513397 A5 JP 2010513397A5 JP 2009542043 A JP2009542043 A JP 2009542043A JP 2009542043 A JP2009542043 A JP 2009542043A JP 2010513397 A5 JP2010513397 A5 JP 2010513397A5
- Authority
- JP
- Japan
- Prior art keywords
- oxadiazol
- phenyl
- indol
- chloro
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 3
- -1 trifluoromethoxy , Difluoromethoxy Chemical group 0.000 claims 3
- QFOCXKVUZZDCDL-UHFFFAOYSA-N 3-[5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C=CN(CCC(O)=O)C3=CC=2)=NO1 QFOCXKVUZZDCDL-UHFFFAOYSA-N 0.000 claims 2
- HLDBXISXBVARTO-UHFFFAOYSA-N 4-[5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C=CN(CCCC(O)=O)C3=CC=2)=NO1 HLDBXISXBVARTO-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 150000003235 pyrrolidines Chemical class 0.000 claims 2
- RYCURDRPWHCXQR-AWEZNQCLSA-N (2s)-3-[5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]-2-methylpropanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C=CN(C[C@H](C)C(O)=O)C3=CC=2)=NO1 RYCURDRPWHCXQR-AWEZNQCLSA-N 0.000 claims 1
- XNSGYCLMPVYDMN-UHFFFAOYSA-N 1-(trifluoromethoxy)piperidine-2-carbonitrile Chemical compound C(#N)C1N(CCCC1)OC(F)(F)F XNSGYCLMPVYDMN-UHFFFAOYSA-N 0.000 claims 1
- JDKAJAKVJGLQIO-UHFFFAOYSA-N 2,2-dimethyl-3-[5-[5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C=1C=C2N(CC(C)(C)C(O)=O)C=CC2=CC=1C(N=1)=NOC=1C(SC=1C(F)(F)F)=CC=1C1=CC=CC=C1 JDKAJAKVJGLQIO-UHFFFAOYSA-N 0.000 claims 1
- QDKQSBXYKYZLMW-UHFFFAOYSA-N 2-[4-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]acetic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CC(O)=O)C=3C=CC=2)=NO1 QDKQSBXYKYZLMW-UHFFFAOYSA-N 0.000 claims 1
- JNCSFNYUKWYUDF-UHFFFAOYSA-N 2-[4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]acetic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CC(O)=O)C=3C=CC=2)=NO1 JNCSFNYUKWYUDF-UHFFFAOYSA-N 0.000 claims 1
- JQVFIRYJMBZLQN-UHFFFAOYSA-N 2-[5-[5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]indol-1-yl]acetic acid Chemical compound C=1C=C2N(CC(=O)O)C=CC2=CC=1C(N=1)=NOC=1C(SC=1C(F)(F)F)=CC=1C1=CC=CC=C1 JQVFIRYJMBZLQN-UHFFFAOYSA-N 0.000 claims 1
- GARZFFFQOZCWNY-UHFFFAOYSA-N 3-(1-butylindol-4-yl)-5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole Chemical compound ClC=1C=C(C=CC1OC(F)(F)F)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCCC GARZFFFQOZCWNY-UHFFFAOYSA-N 0.000 claims 1
- CKMFAHYUCMRLJC-UHFFFAOYSA-N 3-(1-butylindol-4-yl)-5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazole Chemical compound C1(=CC=CC=C1)C=1C=C(SC1C(F)(F)F)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCCC CKMFAHYUCMRLJC-UHFFFAOYSA-N 0.000 claims 1
- GZCAFNMJWRFCPB-UHFFFAOYSA-N 3-[3-bromo-5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C(Br)=CN(CCC(O)=O)C3=CC=2)=NO1 GZCAFNMJWRFCPB-UHFFFAOYSA-N 0.000 claims 1
- IHFJSTWVWRLHRP-UHFFFAOYSA-N 3-[3-chloro-4-[5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C=C(Cl)C2=C1C(N=1)=NOC=1C(SC=1C(F)(F)F)=CC=1C1=CC=CC=C1 IHFJSTWVWRLHRP-UHFFFAOYSA-N 0.000 claims 1
- ATRHHCBTXLJODU-UHFFFAOYSA-N 3-[3-chloro-5-[5-(3-chloro-4-ethoxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OCC)=CC=C1C1=NC(C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)=NO1 ATRHHCBTXLJODU-UHFFFAOYSA-N 0.000 claims 1
- NSXLYJQAZFEOGH-UHFFFAOYSA-N 3-[3-chloro-5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)=NO1 NSXLYJQAZFEOGH-UHFFFAOYSA-N 0.000 claims 1
- KOHQHMAPKUTNNE-UHFFFAOYSA-N 3-[3-chloro-5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)=NO1 KOHQHMAPKUTNNE-UHFFFAOYSA-N 0.000 claims 1
- YEWFYEAYIRWLBU-UHFFFAOYSA-N 3-[3-chloro-5-[5-(4-chloro-3-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC(C=2ON=C(N=2)C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)=C1 YEWFYEAYIRWLBU-UHFFFAOYSA-N 0.000 claims 1
- VWGIWRCFAHCBKK-UHFFFAOYSA-N 3-[3-chloro-5-[5-(4-methoxy-3-phenylphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound COC1=CC=C(C=2ON=C(N=2)C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)C=C1C1=CC=CC=C1 VWGIWRCFAHCBKK-UHFFFAOYSA-N 0.000 claims 1
- XHSNHDLFBNSHHH-UHFFFAOYSA-N 3-[3-chloro-5-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C=1C=C2N(CCC(=O)O)C=C(Cl)C2=CC=1C(N=1)=NOC=1C1=CC=C(OC(F)(F)F)C(Cl)=C1 XHSNHDLFBNSHHH-UHFFFAOYSA-N 0.000 claims 1
- SJDIWNCKZJNHPE-UHFFFAOYSA-N 3-[3-chloro-5-[5-[4-methoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C1=NC(C=2C=C3C(Cl)=CN(CCC(O)=O)C3=CC=2)=NO1 SJDIWNCKZJNHPE-UHFFFAOYSA-N 0.000 claims 1
- YOCISYLTMKQWMT-UHFFFAOYSA-N 3-[3-chloro-5-[5-[4-nitro-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C=1C=C2N(CCC(=O)O)C=C(Cl)C2=CC=1C(N=1)=NOC=1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YOCISYLTMKQWMT-UHFFFAOYSA-N 0.000 claims 1
- CDRBYCWJUGAZCB-UHFFFAOYSA-N 3-[3-chloro-5-[5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C=1C=C2N(CCC(=O)O)C=C(Cl)C2=CC=1C(N=1)=NOC=1C(SC=1C(F)(F)F)=CC=1C1=CC=CC=C1 CDRBYCWJUGAZCB-UHFFFAOYSA-N 0.000 claims 1
- JWIKJHGBIFHLPM-UHFFFAOYSA-N 3-[4-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=NO1 JWIKJHGBIFHLPM-UHFFFAOYSA-N 0.000 claims 1
- XAJVGJHOAIETSC-UHFFFAOYSA-N 3-[4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=NO1 XAJVGJHOAIETSC-UHFFFAOYSA-N 0.000 claims 1
- ZDNCNPFZPVFQLU-UHFFFAOYSA-N 3-[4-[5-(3-ethyl-4-piperidin-1-ylphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound CCC1=CC(C=2ON=C(N=2)C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=CC=C1N1CCCCC1 ZDNCNPFZPVFQLU-UHFFFAOYSA-N 0.000 claims 1
- ZRMYIOJUUABNBB-UHFFFAOYSA-N 3-[4-[5-(4-cyclohexyl-3-ethylphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound CCC1=CC(C=2ON=C(N=2)C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=CC=C1C1CCCCC1 ZRMYIOJUUABNBB-UHFFFAOYSA-N 0.000 claims 1
- FLERAFQOOGRXHE-UHFFFAOYSA-N 3-[4-[5-(5-chloro-6-propan-2-yloxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=NC=C1C1=NC(C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=NO1 FLERAFQOOGRXHE-UHFFFAOYSA-N 0.000 claims 1
- QIHAASGINXICIX-UHFFFAOYSA-N 3-[4-[5-[4-(2-fluorophenyl)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C=CC2=C1C(N=1)=NOC=1C(C=C1C(F)(F)F)=CC=C1C1=CC=CC=C1F QIHAASGINXICIX-UHFFFAOYSA-N 0.000 claims 1
- BGXPNVXUXLUWGQ-UHFFFAOYSA-N 3-[4-[5-[4-(2-methylpropyl)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C(CC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=NO1 BGXPNVXUXLUWGQ-UHFFFAOYSA-N 0.000 claims 1
- FONMSGPEBHUUIV-UHFFFAOYSA-N 3-[4-[5-[4-cyclohexyl-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C=CC2=C1C(N=1)=NOC=1C(C=C1C(F)(F)F)=CC=C1C1CCCCC1 FONMSGPEBHUUIV-UHFFFAOYSA-N 0.000 claims 1
- NORSCQNGKKVMIO-UHFFFAOYSA-N 3-[4-[5-[4-phenyl-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C=CC2=C1C(N=1)=NOC=1C(C=C1C(F)(F)F)=CC=C1C1=CC=CC=C1 NORSCQNGKKVMIO-UHFFFAOYSA-N 0.000 claims 1
- GVFAFIKUOWUAIQ-UHFFFAOYSA-N 3-[4-[5-[4-propan-2-yloxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCC(O)=O)C=3C=CC=2)=NO1 GVFAFIKUOWUAIQ-UHFFFAOYSA-N 0.000 claims 1
- HCWIAVVSUBERJZ-UHFFFAOYSA-N 3-[5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]-2,2,3-trifluoropropanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C=CN(C3=CC=2)C(F)C(F)(F)C(O)=O)=NO1 HCWIAVVSUBERJZ-UHFFFAOYSA-N 0.000 claims 1
- JXFAYGCVJMEDKI-UHFFFAOYSA-N 3-[5-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C=CN(CCC(O)=O)C3=CC=2)=NO1 JXFAYGCVJMEDKI-UHFFFAOYSA-N 0.000 claims 1
- RAXQVKOQRHWHOU-UHFFFAOYSA-N 3-[5-[5-[3-phenyl-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]propanoic acid Chemical compound C=1C=C2N(CCC(=O)O)C=CC2=CC=1C(N=1)=NOC=1C(C=1)=CC=C(C(F)(F)F)C=1C1=CC=CC=C1 RAXQVKOQRHWHOU-UHFFFAOYSA-N 0.000 claims 1
- WHHGUZLUCIYBPL-UHFFFAOYSA-N 4-[4-[5-(3-bromo-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(Br)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 WHHGUZLUCIYBPL-UHFFFAOYSA-N 0.000 claims 1
- SKMHVWFGAFXNPS-UHFFFAOYSA-N 4-[4-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 SKMHVWFGAFXNPS-UHFFFAOYSA-N 0.000 claims 1
- APHXDFHTQCIQBC-UHFFFAOYSA-N 4-[4-[5-(3-cyano-4-phenylphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=CC=C2N(CCCC(=O)O)C=CC2=C1C(N=1)=NOC=1C(C=C1C#N)=CC=C1C1=CC=CC=C1 APHXDFHTQCIQBC-UHFFFAOYSA-N 0.000 claims 1
- UHURKDFLIMINLN-UHFFFAOYSA-N 4-[4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 UHURKDFLIMINLN-UHFFFAOYSA-N 0.000 claims 1
- NFIGDBFIDKDNIG-UHFFFAOYSA-N 4-[4-[5-(5-chloro-6-propan-2-yloxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=NC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 NFIGDBFIDKDNIG-UHFFFAOYSA-N 0.000 claims 1
- ZOAACYIIORBWGO-UHFFFAOYSA-N 4-[4-[5-[3-chloro-4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(Cl)C(CC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 ZOAACYIIORBWGO-UHFFFAOYSA-N 0.000 claims 1
- GJFQCFCPADTPMV-UHFFFAOYSA-N 4-[4-[5-[3-cyano-4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(C#N)C(CC(C)C)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 GJFQCFCPADTPMV-UHFFFAOYSA-N 0.000 claims 1
- LWXBLIIYLSYXCB-MRXNPFEDSA-N 4-[4-[5-[4-[(2r)-butan-2-yl]oxy-3-cyanophenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(C#N)C(O[C@H](C)CC)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 LWXBLIIYLSYXCB-MRXNPFEDSA-N 0.000 claims 1
- LWXBLIIYLSYXCB-INIZCTEOSA-N 4-[4-[5-[4-[(2s)-butan-2-yl]oxy-3-cyanophenyl]-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid Chemical compound C1=C(C#N)C(O[C@@H](C)CC)=CC=C1C1=NC(C=2C=3C=CN(CCCC(O)=O)C=3C=CC=2)=NO1 LWXBLIIYLSYXCB-INIZCTEOSA-N 0.000 claims 1
- QJIVNHOOAVDJGU-UHFFFAOYSA-N 5-[3-chloro-4-(trifluoromethoxy)phenyl]-3-(1-propylindol-4-yl)-1,2,4-oxadiazole Chemical compound ClC=1C=C(C=CC1OC(F)(F)F)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCC QJIVNHOOAVDJGU-UHFFFAOYSA-N 0.000 claims 1
- WATSNPHZRLYSFP-UHFFFAOYSA-N 5-[4-methoxy-3-(trifluoromethyl)phenyl]-3-(1-propylindol-4-yl)-1,2,4-oxadiazole Chemical compound COC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCC)C(F)(F)F WATSNPHZRLYSFP-UHFFFAOYSA-N 0.000 claims 1
- WKPUDPBVSXJIFA-UHFFFAOYSA-N 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-(1-propylindol-4-yl)-1,2,4-oxadiazole Chemical compound C1(=CC=CC=C1)C=1C=C(SC1C(F)(F)F)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCC WKPUDPBVSXJIFA-UHFFFAOYSA-N 0.000 claims 1
- PZHHBSOVEVNOGW-UHFFFAOYSA-N 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-(1-propylindol-5-yl)-1,2,4-oxadiazole Chemical compound C1(=CC=CC=C1)C=1C=C(SC1C(F)(F)F)C1=NC(=NO1)C=1C=C2C=CN(C2=CC1)CCC PZHHBSOVEVNOGW-UHFFFAOYSA-N 0.000 claims 1
- VXNIDFMYHIAKQT-UHFFFAOYSA-N 5-[5-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]indol-1-yl]pentanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NC(C=2C=C3C=CN(CCCCC(O)=O)C3=CC=2)=NO1 VXNIDFMYHIAKQT-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- HGFOFHRQIDSJNF-UHFFFAOYSA-N CCC(C(O)=O)N1C2=CC=CC(C3=NOC(C(C=C4)=CC(C(F)(F)F)=C4C4=CC=CC=C4)=N3)=C2C=C1 Chemical compound CCC(C(O)=O)N1C2=CC=CC(C3=NOC(C(C=C4)=CC(C(F)(F)F)=C4C4=CC=CC=C4)=N3)=C2C=C1 HGFOFHRQIDSJNF-UHFFFAOYSA-N 0.000 claims 1
- VGAJWLUXQVSFLA-UHFFFAOYSA-N ClC1=CN(C2=CC=C(C=C12)C1=NOC(=N1)C1=CC(=C(C=C1)OC)Cl)CCC Chemical compound ClC1=CN(C2=CC=C(C=C12)C1=NOC(=N1)C1=CC(=C(C=C1)OC)Cl)CCC VGAJWLUXQVSFLA-UHFFFAOYSA-N 0.000 claims 1
- LMLQGCXGHXLBJC-UHFFFAOYSA-N ClC1=CN(C2=CC=C(C=C12)C1=NOC(=N1)C1=CC(=C(C=C1)OCCC)Cl)CCC Chemical compound ClC1=CN(C2=CC=C(C=C12)C1=NOC(=N1)C1=CC(=C(C=C1)OCCC)Cl)CCC LMLQGCXGHXLBJC-UHFFFAOYSA-N 0.000 claims 1
- WDSAYRCDGSHDCT-UHFFFAOYSA-N ClC=1C=C(C=NC1N1CCCC1)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCC Chemical compound ClC=1C=C(C=NC1N1CCCC1)C1=NC(=NO1)C1=C2C=CN(C2=CC=C1)CCC WDSAYRCDGSHDCT-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0625647.3 | 2006-12-21 | ||
| GB0625647A GB0625647D0 (en) | 2006-12-21 | 2006-12-21 | Compounds |
| GB0707615.1 | 2007-04-19 | ||
| GB0707615A GB0707615D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
| PCT/EP2007/064185 WO2008074821A1 (en) | 2006-12-21 | 2007-12-19 | Indole derivatives as s1p1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513397A JP2010513397A (ja) | 2010-04-30 |
| JP2010513397A5 true JP2010513397A5 (enExample) | 2010-08-19 |
| JP5309034B2 JP5309034B2 (ja) | 2013-10-09 |
Family
ID=39283563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542043A Expired - Fee Related JP5309034B2 (ja) | 2006-12-21 | 2007-12-19 | Ｓ１ｐ１受容体アゴニストとしてのインドール誘導体 |
Country Status (32)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012738A (es) | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| CL2008001099A1 (es) * | 2007-04-19 | 2008-10-24 | Glaxo Group Ltd | Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras. |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| HUE025984T2 (hu) | 2008-05-14 | 2016-05-30 | Scripps Research Inst | Szfingozin foszfát receptor új modulátorai |
| WO2009151626A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| US8217028B2 (en) | 2008-06-20 | 2012-07-10 | Glaxo Group Limited | 1,2,4-oxadiazole indole compounds |
| DK2307007T3 (da) * | 2008-07-23 | 2014-11-10 | Novartis Ag | Sphingosin-1-phosphat-receptormodulatorer samt deres anvendelse til behandling af muskelinflammation |
| HRP20161133T1 (hr) | 2008-07-23 | 2016-12-02 | Arena Pharmaceuticals, Inc. | DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA |
| CN105816453B (zh) * | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| CA2743397C (en) | 2008-12-18 | 2017-02-28 | Mathilde Muzerelle | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) * | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2241558A1 (en) * | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| GB0910667D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| WO2011005295A1 (en) * | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| UA107360C2 (en) * | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| SI2498610T2 (sl) | 2009-11-13 | 2024-10-30 | Receptos Llc | Selektivni modulatorji receptorja sfingozin-1-fosfata in postopki kiralne sinteze |
| WO2011072488A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| CA2786994C (en) | 2010-01-27 | 2018-01-16 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CN105503882B (zh) * | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| ES2548683T3 (es) | 2010-04-23 | 2015-10-20 | Bristol-Myers Squibb Company | Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1 |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| PT2672823T (pt) | 2011-02-07 | 2016-11-21 | Biogen Ma Inc | Agentes que modulam s1p |
| WO2012158550A2 (en) | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| EP3492465B1 (en) * | 2016-07-22 | 2021-03-24 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | S1p1 agonist and application thereof |
| EP3518922B1 (en) * | 2016-09-29 | 2026-02-11 | Receptos LLC | Compounds and methods for treating lupus |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN110627778B (zh) * | 2018-06-25 | 2023-01-24 | 中国科学院上海药物研究所 | 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用 |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| TW202131921A (zh) | 2019-10-31 | 2021-09-01 | 瑞士商愛杜西亞製藥有限公司 | Cxcr7拮抗劑與s1p1受體調節劑之組合 |
| WO2021112461A1 (ko) | 2019-12-03 | 2021-06-10 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
| US12604895B2 (en) | 2020-02-11 | 2026-04-21 | Syngenta Crop Protection Ag | Pesticidally active cyclic amine compounds |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939238A1 (de) | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5523312A (en) | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| CA2524867A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| JP5024039B2 (ja) | 2005-02-25 | 2012-09-12 | 小野薬品工業株式会社 | インドール化合物およびその用途 |
| BRPI0609668A2 (pt) | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用 |
| JP2009506046A (ja) | 2005-08-23 | 2009-02-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制剤化合物および組成物 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP2007262009A (ja) | 2006-03-29 | 2007-10-11 | Dai Ichi Seiyaku Co Ltd | ヘテロアリール低級カルボン酸誘導体 |
| MX2008012738A (es) * | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| CL2007002593A1 (es) | 2006-09-07 | 2008-06-13 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer. |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| CL2008001099A1 (es) | 2007-04-19 | 2008-10-24 | Glaxo Group Ltd | Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras. |
-
2007
- 2007-12-17 JO JO2007554A patent/JO2701B1/en active
- 2007-12-19 PL PL07857808T patent/PL2091949T3/pl unknown
- 2007-12-19 BR BRPI0721127-9A patent/BRPI0721127A2/pt not_active IP Right Cessation
- 2007-12-19 JP JP2009542043A patent/JP5309034B2/ja not_active Expired - Fee Related
- 2007-12-19 DK DK10158582.6T patent/DK2206710T3/da active
- 2007-12-19 HR HR20110456T patent/HRP20110456T1/hr unknown
- 2007-12-19 PL PL10158582T patent/PL2206710T3/pl unknown
- 2007-12-19 US US12/520,145 patent/US8101775B2/en not_active Expired - Fee Related
- 2007-12-19 EP EP07857808A patent/EP2091949B1/en not_active Not-in-force
- 2007-12-19 SG SG2011095114A patent/SG177914A1/en unknown
- 2007-12-19 AU AU2007336224A patent/AU2007336224B2/en not_active Ceased
- 2007-12-19 CN CN201210396720.5A patent/CN103012390B/zh not_active Expired - Fee Related
- 2007-12-19 ES ES10158582T patent/ES2389879T3/es active Active
- 2007-12-19 PT PT10158582T patent/PT2206710E/pt unknown
- 2007-12-19 PT PT07857808T patent/PT2091949E/pt unknown
- 2007-12-19 CA CA2673468A patent/CA2673468C/en not_active Expired - Fee Related
- 2007-12-19 NZ NZ577387A patent/NZ577387A/en not_active IP Right Cessation
- 2007-12-19 MX MX2009006882A patent/MX2009006882A/es active IP Right Grant
- 2007-12-19 MY MYPI2012004367A patent/MY156822A/en unknown
- 2007-12-19 DK DK07857808.5T patent/DK2091949T3/da active
- 2007-12-19 WO PCT/EP2007/064185 patent/WO2008074821A1/en not_active Ceased
- 2007-12-19 SI SI200731001T patent/SI2206710T1/sl unknown
- 2007-12-19 MY MYPI20092612A patent/MY148470A/en unknown
- 2007-12-19 EA EA200970612A patent/EA017406B1/ru not_active IP Right Cessation
- 2007-12-19 KR KR1020097012841A patent/KR101495927B1/ko not_active Expired - Fee Related
- 2007-12-19 TW TW096148543A patent/TWI393564B/zh not_active IP Right Cessation
- 2007-12-19 EP EP10158582A patent/EP2206710B1/en not_active Not-in-force
- 2007-12-19 AR ARP070105729A patent/AR064452A1/es unknown
- 2007-12-19 SI SI200730670T patent/SI2091949T1/sl unknown
- 2007-12-19 AT AT07857808T patent/ATE509927T1/de active
- 2007-12-20 CL CL200703755A patent/CL2007003755A1/es unknown
-
2008
- 2008-01-02 PE PE2008000023A patent/PE20081398A1/es not_active Application Discontinuation
- 2008-01-02 PE PE2012000146A patent/PE20121076A1/es not_active Application Discontinuation
-
2009
- 2009-06-04 IL IL199187A patent/IL199187A/en not_active IP Right Cessation
- 2009-06-05 DO DO2009000133A patent/DOP2009000133A/es unknown
- 2009-06-17 MA MA32003A patent/MA30999B1/fr unknown
- 2009-06-23 NO NO20092385A patent/NO20092385L/no not_active Application Discontinuation
- 2009-07-13 CR CR10922A patent/CR10922A/es unknown
-
2011
- 2011-07-19 CY CY20111100700T patent/CY1111702T1/el unknown
-
2012
- 2012-08-29 HR HRP20120685TT patent/HRP20120685T1/hr unknown
- 2012-09-20 CY CY20121100862T patent/CY1113131T1/el unknown
-
2014
- 2014-07-01 CR CR20140316A patent/CR20140316A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519680A5 (enExample) | ||
| JP2006518763A5 (enExample) | ||
| ES2617221T3 (es) | Derivados de 3-(2-aril-cicloalquenilmetil)-oxazolidin-2-ona como inhibidores de la proteína de transferencia de ésteres de colesterol (CETP) | |
| HRP20110456T1 (hr) | Derivati indola kao agonisti receptora s1p1 | |
| JP2010533722A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2009519965A5 (enExample) | ||
| JP2016515536A5 (enExample) | ||
| ME02047B (me) | Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost | |
| JP2013542937A5 (enExample) | ||
| RU2021127810A (ru) | Замещенные гетероарилом пиридины и способы применения | |
| JP2008513515A5 (enExample) | ||
| JP2010539152A5 (enExample) | ||
| TW200539854A (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| JP2018535999A5 (enExample) | ||
| JP2014500330A5 (enExample) | ||
| JP2007511485A5 (enExample) | ||
| JP2019518036A5 (enExample) | ||
| RU2017125365A (ru) | Производные азабициклооктана в качестве агонистов fxr для применения при лечении заболеваний печени и желудочно-кишечных заболеваний | |
| JP2022549086A5 (enExample) | ||
| RU2012132692A (ru) | Новые ингибиторы s-нитрозоглутатионредуктазы | |
| RU2013112122A (ru) | Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы | |
| JP2007523181A5 (enExample) | ||
| CN112955448A (zh) | 芳环或芳杂环类化合物及其制备方法和医药用途 | |
| JP2013537913A5 (enExample) |